-
US Mortgage Rate Falls for Fourth Week but Remains Above 7%
-
US Jobless Claims Rise to 200,000 but Layoffs Remain Historically Low
-
Italy Raises 2026 Growth View but Warns Energy Will Keep Inflation High
-
Godzilla Minus Zero Review: Takashi Yamazaki’s Anti-Nuclear Allegory
-
Euro-Area Growth Slows to 0.4% While Employment Stalls
-
DA Demands No-Work-No-Pay for Striking Municipal Workers in Coalition Talks
-
UK Economy Grows 0.7% in Third Quarter as Services Lead Expansion
-
US Wholesale Inflation Eases Monthly but Hits a Four-Year Annual High
-
India's Retail Inflation Reaches 6.09% as Food Prices Accelerate
-
India's Wholesale Inflation Jumps to 12.29% as Fuel Costs Surge
-
Malta Emerges as Premier Low-Season Destination for UK Travelers
-
China's October Activity Data Reveal a Weak Start to the Fourth Quarter
-
Japan's Economy Edges Into Contraction as Costly Oil Weighs on Demand
-
Philippines Urges ASEAN and China to Accelerate South China Sea Code of Conduct
-
UK Home Asking Prices Drop £6,745 in November Amid High Mortgage Rates
-
Mbeki Claims No Progress Since 2018; Author Cites Infrastructure and Economic Gains
-
Alex Georgiev Sets Personal Record to Win NCAA Pole Vault at Penn Relays
-
Qatar's Amir and Venezuelan Acting President Discuss Energy Cooperation
-
Emerging Growth Research Highlights Criticality of First Phosphate G7-Backed LFP Battery Onshoring Solution as Cleantech Sector Accelerates Post U.S. Midterms
-
SMX Brings a New Level of Transparency to Gold Trading Through trueGold Technology
-
Westell Technologies, Inc. Announces Its Commencing a Tender Offer
-
Rescue Intellitech Expands Professional Decontamination Portfolio for Fire Departments with DeconWasher(TM) Pro S
-
MicroVision Lidar Powers Commercial Driverless Trucking at Scale with Kodiak AI
-
Expecting a Refund but Owe Back Taxes? Clear Start Tax Explains How the IRS Offset Program Takes It First
-
Cardiff Lexington Announces Third Quarter 2026 Financial Results
-
Ainos Reports Third Quarter 2026 Results and Highlights Expanding AI Nose Commercial Momentum
-
SMX: The Future of Gold Will Be Defined by What We Know About It -Powering Verified Trade and Tokenisation
-
NuRAN Wireless Eliminates Floating-Price Preferred Overhang and Locks In a Fixed C$1.20 Conversion Price
-
GameSquare Holdings Reports 2026 Third Quarter Results with Revenue up 77% YoY and Net Income Reaches $10.1 Million
-
ValorPay UAB Goes Live on T2, the Eurosystem's Real-Time Settlement System
-
CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline
-
XCF Global Reports Third Quarter 2026 Financial Results & Affirms 2027 Outlook
-
NextSource Materials Appoints Eugene Lee as Chief Financial Officer
-
International Battery Metals Ltd. Reports Second Quarter of Fiscal Year 2027 Financial Results
-
Abasca Resources Engages Northern Arc Public Affairs to Advance Federal Engagement on the Loki Flake Graphite Project
-
AsiaFIN Holdings Corp. Announces Third Quarter 2026 Results, Reporting Strong Nine-Month Financial Performance with Improved Margins
-
Thalia Therapeutics PLC Announces Promising Interim Phase I Data for miRisten in AML
-
Strategic Metals Reports Promising Results From the Rusty and Ranch Projects
-
Golden Minerals Reports Third Quarter 2026 Financial Results
-
OBI Pharma Signs Collaboration and License Agreement with Novartis
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 16
-
Blue Chip Capital Group Announces Quotation of its Common Stock on the OTCID and Updates Status of Initial Regulatory Compliance
-
Sharecare Partners With HomeTown Health to Bring AskMD, Funded Through the GREAT Health Program, to More Rural Hospitals and Patients Across Georgia
-
Spartan Capital Adds Institutional Investor, Upsizes Credit Facility to $100 Million
-
Diné Development Corporation Named 2026 Minority-Owned Business of the Year by Dayton Business Journal
-
Orlando Dreamers Announce Hundreds of Millions of Additional Financing Under Initial Letter of Intent
-
How to Remotely Access a PLC? Improve Maintenance Efficiency with InHand 4G/5G Industrial Routers
-
Graid Technology Extends VROC(TM) to AMD EPYC(TM) Platforms, Expanding Choice in Enterprise RAID
-
SMX Targets the Missing Link in Global Gold Markets: Proof
-
Lifeloc Reports Third Quarter 2026 Results
New Horizon Medical Solutions Expands Precise Bioscience Product Portfolio with Launch of AdvoGraft One and AdvoGraft Membrane Dual
Natural amniotic membrane-based wound care solutions with CMS-approved Q codes plus billing and reimbursement pathways for healthcare providers and payers available now.
LAS VEGAS, NV / ACCESS Newswire / June 26, 2025 / New Horizon Medical Solutions, a leader in advanced biologics and wound care solutions, through its wholly-owned subsidiary, Precise Bioscience, LLC, announces the launch of AdvoGraft™ One and AdvoGraft Membrane Dual, two biologic wound care products that support natural healing by protecting both acute and chronic wounds. Both products use processed human placental tissue to better serve as a barrier between the wound and the surrounding environment during the healing process. Their availability is supported by newly approved CMS HCPCS Level II codes, Q4380 and Q4382, to simplify billing and reimbursement.
"As a company, we're committed to advancing biologic wound care through clinically trusted, natural solutions and to growing the Precise Bioscience product group," said Will Hall, chief executive officer, New Horizon Medical Solutions. "The launch of AdvoGraft One and AdvoGraft Membrane Dual marks a significant milestone in that mission and in our mission as a company to offer the most comprehensive product portfolio for our providers and patients alike."
AdvoGraft One (Q code Q4380): Key features and benefits
Natural solution
Single-layer amniotic membrane from human placental tissue, processed and sterilized for safe, biologically sourced wound care.Clinically supported
Provides a protective cover for various wound sizes and types.Regulatory compliance
Compliant with section 361 of the Public Health Service Act and 21 CFR part 1271.Simplified billing
Q code Q4380 ("AdvoGraft One, per square centimeter") ensures easier reimbursement for clinicians and payers.Easy handling
Sterile, room temperature-stored, and ready for physician application.Available in: 1x1, 2x2, 2x3, 2x4, 4x4, 4x6, 4x8 and 10x15cm sizes
AdvoGraft Membrane Dual (Q code Q4382): Enhanced clinical benefits
Dual-layer membrane
Combines amniotic and chorionic membranes for greater structural support.Comprehensive wound protection
Designed for wounds needing more robust coverage and support.Trusted product
Regulated under section 361 of the PHS Act and 21 CFR part 1271 for consistency and efficacy.Streamlined reimbursement
Q code Q4382 ("AdvoGraft Membrane Dual, per square centimeter") makes billing and claims easier for advanced wound care.Versatile use
Available in multiple sizes, sterile, and ready to use, stored at room temperature.Available in: 1x1, 2x2, 2x3, 2x4, 4x4, 4x6, 4x8 and 10x15cm sizes
A reliable, biologic wound care solution
"The offering of the AdvoGraft family reflects our focus on furthering product development and championing long-term patient care," said D. Christopher Keil, SVP, strategy & corporate development, New Horizon Medical Solutions. "By adding additional CMS-approved Q codes, we're not only simplifying access to advanced wound care solutions for clinicians and patients but also ensuring practitioners have choices when making medically important decisions."
For more information
Healthcare professionals and payers can learn more about AdvoGraft One and AdvoGraft Membrane Dual and the Precise Bioscience product line at nhmedical.com or precisebioscience.com and by contacting New Horizon Medical Solutions at (702) 960-2913 or [email protected].
About New Horizon Medical Solutions
New Horizon Medical Solutions LLC focuses on biologically derived wound care products that meet high standards for safety and performance. Our commitment to natural, reliable solutions helps clinicians, payers, and patients redefine wound care with effective, trusted therapies. Precise Bioscience, LLC is a wholly owned subsidiary of New Horizon Medical Solutions providing the most advanced wound care solutions including Xcell Amnio Matrix™, Xcellerate® and more.
Media contact
Julian Rogers
Director of Corporate Marketing
[email protected]
702-960-2913
SOURCE: New Horizon Medical Solutions
View the original press release on ACCESS Newswire
W.Stewart--AT